Results 211 to 220 of about 135,255 (300)

In Vivo Fluorescent Melanoma Model: Electroporation Plus Magnetic Hyperthermia Significatively Reduces Tumor Size, Preliminary Results. [PDF]

Pharmaceutics
Molina-Pineda A, Vizcarra-Ramos S, Gutiérrez-Ortega A, Aguilar-Lemarroy A, Jave-Suárez LF, Cano ME, Hernández-Gutiérrez R.   +6 more
europepmc   +1 more source

The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer

BJU International, EarlyView.
Objectives Primary objective: to determine whether prostate gland partial ablation (PA) has non‐inferior oncological treatment success vs radical treatment (RT) of localised intermediate‐risk prostate cancer (irPCa). Secondary objectives: to compare (i) participant‐reported urinary and sexual dysfunction side effects, (ii) short/medium term serious ...
Richard J. Bryant, Tom Leslie, Marc Laniado, Abhishek Sharma, Alistair Grey, John Withington, Christopher Blick, Edward Streeter, Sanjeev Kotwal, Oliver Hulson, William Cross, Daniel W. Good, Altan Omer, Taimur T. Shah, Nishant Bedi, Luke Stroman, Caroline Moore, Prasanna Sooriakumaran, Hashim U. Ahmed, Simon F. Brewster, Vicki S. Barber, Aimi Hewitt, Clare Calvert, Jessica Scaife, Derek Shepherd, Filipa Landeiro, Jane Wolstenholme, Philip Camilleri, Clare Verrill, Shelagh Lovell, Martin Pirkl, Fergus Gleeson, Roxanne Williams, Jo Cook, Catherine R. Holt, Martyn Hill, Jonathan Cook, James Radford, Ioana R. Marian, Ruth Macpherson, Daisy Elliott, Jenny L. Donovan, Freddie C. Hamdy   +42 more
wiley   +1 more source

Transurethral ultrasound ablation (TULSA) for prostate cancer: a systematic review and meta‐analysis

BJU International, EarlyView.
Objective Our objective was to synthesise evidence on oncological, functional and safety outcomes of magnetic resonance imaging‐guided transurethral ultrasound ablation (TULSA) for primary and recurrent prostate cancer. Methods MEDLINE, Embase, Web of Science and Scopus were systematically searched from inception to July 2025. The primary outcomes were
Eugene Wang, Xinyi Wei, Yajat Dua, Marlon Perera, Jeremy Grummet   +4 more
wiley   +1 more source

Image-fusion-guided focal irreversible electroporation for prostate cancer: Step-by-step technique. [PDF]

BJUI Compass
Kaneko M, Inoue Y, Eskenazi F, Abreu AL.
europepmc   +1 more source

PDE4D and PDE3B orchestrate distinct cAMP microdomains in 3T3‐L1 adipocytes

British Journal of Pharmacology, EarlyView.
Basal conditions: •Ins/PDE3B lowers cytoplasmic cAMP (cyt‐cAMP) without affecting plasma membrane cAMP (pm‐cAMP). •Insulin decreases lipid droplet cAMP (LD‐cAMP) independent of PDE3B. •FGF1/PDE4D modestly reduces both cyt‐ and pm‐cAMP, while PDE4D alone can modulate LD‐cAMP. ISO stimulation: •Ins/PDE3B has minimal impact on cyt‐cAMP.
Johannes Krier, David Spähn, David Arturo Juarez Lopez, Judith L. Nono, Judith Seigner, Lisa Jacob, Siegfried Ussar, Robert Lukowski, Andreas L. Birkenfeld, Gencer Sancar   +9 more
wiley   +1 more source

Direct phospho-proteoform delivery reveals a degradation-prone monomeric state of 14-3-3. [PDF]

Chem Sci
Mathis MH, Stanisheuski S, Mehl RA, Cooley RB.   +3 more
europepmc   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Simple Electroporation of <i>Chlamydomonas reinhardtii</i> Strains With an Intact Cell Wall. [PDF]

Bio Protoc
Meßmer M, de Carpentier F, Lam E, Hong M, Wakao S, Schroda M, Niyogi KK.   +6 more
europepmc   +1 more source

Repurposed catechol‐O‐methyltransferase inhibitors tolcapone and entacapone preferentially suppress aggregation and seeding of P301 mutant tau in human neuronal models

British Journal of Pharmacology, EarlyView.
Background and purpose Pathogenic aggregation and propagation of seed‐competent TAU assemblies drive tauopathies. MAPT P301 mutations accelerate aggregation and enhance seed competence, yet pharmacological strategies selectively targeting these pathogenic species remain limited.
Ihor Kozlov, Yu‐Sheng Hung, Sudeep Roy, Alladi Charanraj Goud, Roman Kouřil, Yu‐Hui Wong, Viswanath Das   +6 more
wiley   +1 more source